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Abstract. In the Bolivian Chaco, south-east of Bolivia, studies conducted over the past three decades reported
hepatitis A virus (HAV) andHelicobacter pylori seroprevalences above 90%and60%, respectively. Hepatitis E virus (HEV)
prevalence was previously found to be 6–7% but is probably an underestimate because of the poor sensitivity of the
assays used. In November 2013, we conducted a cross-sectional study of 263 healthy volunteers from two rural com-
munities of the Bolivian Chaco, aiming to reassess HAV, HEV, and H. pylori seroprevalence 10–20 years following the
previous surveys. Hepatitis A virus seroprevalence was 95%, with universal exposure after the first decade of life; HEV
seroprevalencewas considerably higher (31–35%) than that previously reported;H. pylori seroprevalencewas 59%,with
an age-dependent distribution. The high prevalence of these infections suggests that major efforts are still needed to
reduce fecal–oral transmission and to improve human health in the Bolivian Chaco.
INTRODUCTION
Hepatitis A is a common form of acute viral hepatitis
worldwide. Hepatitis A virus (HAV) is transmitted by the
fecal–oral route because of ingestion of contaminated food or
water or through direct contact with an infectious individual.
The spread of the virus is strongly correlated with poor so-
cioeconomic and hygienic conditions. In low-income coun-
tries, where access to safe water and sanitation standards are
inadequate, HAV is highly endemic, and infections occur al-
most universally in early childhood.1,2 The risk of disease after
acute HAV infection varies by age, and the clinical course in
children is usually asymptomatic ormild. By contrast, infected
adolescents and adults more frequently develop classic
symptoms of hepatitis, including jaundice. The infection in-
duces lifelong protection, with detectable anti-HAV immuno-
globulins (Ig)G.
Hepatitis E virus (HEV) has an extensive global distribution
and causes epidemics and sporadic cases in many low-
income countries. In endemic areas, HEVgenotypes (gt) 1 and
2 are transmitted by the fecal–oral route, primarily through
contaminated drinking water, but person-to-person trans-
mission is uncommon.3 Unlike other hepatitis viruses, large
reservoirs of HEV gt 3 and 4 have been recognized in various
animal species, such as pigs, rabbits, boar, and deer. These
observations suggest zoonotic transmission, which has been
well documented in high-income countries, mainly in Europe.
Hepatitis E virus infection by gt 1 and 2 causes an acute, self-
limiting hepatitis, predominantly in young adults. Although the
symptoms are generally mild, fulminant infection may occur,
especially in pregnant women. In many developed countries,
gt 3 and 4 are the dominant circulating HEV and cause acute
hepatitis usually in older males and chronic infection in the
immunosuppressed. In contrast to HAV, global HEV seropre-
valence is less than 10% in children younger than 10 years, and
the peak of incidence occurs in young adults aged between
15 and 40 years in many areas endemic for HEV gt 1 and 2.3,4
Helicobacter pylori is a common bacterium that infects the
gastric mucosa of nearly half of the human population. Prev-
alence is higher in developing than in developed countries,
and it seems to be related to inadequate sanitation practices,
low social class, and overcrowded or high-density living
conditions.5 Although the infection is likely to spread from
person to person, the precise route of transmission is con-
troversial, as data supporting fecal–oral, oral–oral, gastric–
oral, waterborne, and zoonotic transmission have been
reported.5,6 Most of the infections occur in early childhood
and, if not treated, persist lifelong. Chronic infection with
H. pylori is associated with gastrointestinal tract disorders,
ranging from chronic gastritis to gastric adenocarcinoma,
gastric lymphoma, and peptic ulcer.5
In the Bolivian Chaco, a tropical region in the south-east of
Bolivia, previous studies showed a high prevalence of HAV,
above 90% in the general population. However, a significant
decrease in the HAV seroprevalence, from 86.9% to 64.7%,
was observed among children aged 1–5 years, during the
period 1987–1997.7,8 In the second survey, HEV seropreva-
lencewas initially assessed in twoareas of theBolivianChaco,
reporting an overall prevalence of 7.3%, with significantly
lower levels in individuals £ 30 years of age.8 In 2006, a further
study in the same area showed a similar seroprevalence (6%).
However, both these previous results are likely to be signifi-
cant underestimates of HEV seroprevalence because of the
poor sensitivity of the assays used.9 As far as H. pylori is
concerned, in the same population surveyed for HAV and
HEV in 1997, the prevalence of specific antibodies was 60.7%
(A. Bartoloni, unpublished data).
In this study, the populations of two rural communities in
the Bolivian Chaco were studied to 1) evaluate the trend of
HAV seroprevalence 16 years after the last assessment; 2)
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reassess the HEV seroprevalence using more accurate as-
says; 3) evaluate H. pylori seroprevalence, its distribution by
age, and potential association with the other two fecal–oral
transmitted infections in that area.
MATERIALS AND METHODS
Study design and population. A population-based cross-
sectional studywas conducted inNovember 2013, in two rural
communities of the Bolivian Chaco. The Chaco region is a
semi-arid, homogeneous ecological zone, situated be-
tween the latitudes 17599–22219 South and the longitudes
64319–58519 West, and is approximately 127,755 km2 in
size. The region is sparsely populated and includes three de-
partments (Santa Cruz, Chuquisaca, and Tarija) and five
provinces (Cordillera, Luis Calvo, Hernando Siles, Gran
Chaco, and O’Connor). The surveyed communities were
Bartolo (16669S; 64049W; municipality of Monteagudo,
Hernando Siles Province, Department of Chuquisaca) and
Ivamirapinta (19459S; 63479W; municipality of Gutierrez,
Cordillera Province, Department of Santa Cruz). In each
community, the studywas first explained during a preparatory
meeting, involving local health care providers and community
leaders of the Guaranı́ political organization (Asamblea del
Pueblo Guaranı́). With their collaboration, information about
the total number of inhabitants and household locations was
collected. Moreover, they helped to disseminate the invitation
to participate, which was directed to all individuals of the
communities during public meetings. The sample size was
determined based on an expected prevalence of HAV,
H. pylori, and HEV antibodies of 90%, 60%, and 20%, re-
spectively, with a worst acceptable error of 5% and a confi-
dence interval (CI) of 95%. A total of 263 healthy volunteers
were consecutively enrolled, representing 50% and 25%
of the populations of Bartolo and Ivamirapinta, respectively.
Demographic data (sex and age) were recorded, and blood
samples for testing were taken. The study population lives in
poor dwellings with walls of sticks, straw and clay, and
thatched roofs. The local economy is basedon agriculture and
animal farming. In the studyarea, domestic animals, especially
dogs, poultry, and swine, are present in almost all the
households. Inhabitants live in close contact with animals,
which freely migrate from household to household, in the
absence of adequate housing or fencing.
The study was devised and conducted in agreement with
theMinistry of Health of Bolivia (within theConvenioMinisterio
de Salud y Deportes, Estado Plurinacional de Bolivia/Cátedra
de Enfermedades Infecciosas, Universidad de Florencia, Italia)
and with the support of the Guaranı́ political organization
(Asamblea del PuebloGuaranı́). Ethical approval for the study
was obtained from both the above-mentioned institutions.
Serologic assays. Sera, obtained from a sample of 5 mL
venous blood, were stored at −20C in Bolivia, transported to
Italy, and stored at −70C until tested. In July 2016, the anony-
mizedsampleswere testedwith1) twocommercial anti-HEV IgG
enzyme-linked immunosorbent assay (ELISA) kits (DIA.PRO Srl,
Milan, Italy; Wantai Biological Pharmacy Enterprise, Beijing,
China); 2) a commercial chemiluminescence immunoassay for
anti-HAV IgG (Architect HAVAb-IgG; Abbott Laboratories,
Abbott Park, IL); and 3) a commercial enzyme immunoassay
for detecting anti–H. pylori IgG (Premier®H. pylori; Meridian
Bioscence, Milan, Italy). The assays were performed and
interpreted according to the manufacturers’ instructions.
Statistical analysis. Data were entered into a spreadsheet,
using Microsoft Excel 2010 software (Microsoft Corp., Red-
mond, WA). Statistical analysis of the data was performed with
STATA 11.0 (StataCorp, College Station, TX). Frequencies and
percentages with 95% CIs for categorical variables, medians
and interquartile ranges (IQRs) for continuous variables were
calculated. The Mann–Whitney test was used to compare the
median age. The Cochran–Mantel–Haenszel test stratified for
age classes was used to compare results between communi-
ties. Concordance between the two commercial anti-HEV IgG
ELISA was evaluated by computing the k statistics, with a k-
value ³ 0.75 representing excellent agreement. The χ2 test (or
Fisher’s exact test, when appropriate) and logistic regression
were used to investigate the association of the positive ELISA
test with sex and age. Anti-HEV IgG borderline results were
excluded from statistical analysis. Results were considered
statistically significant when the P value was £ 0.05.
RESULTS
Demographic data. In total, 263 samples were collected,
but six samples were excluded from further analysis because
of absent or incomplete participant details. Of those 257 in-
dividuals, 113 were from Bartolo and 144 from Ivamirapinta;
overall, 51% (131/257) were female, and the median age was
27years (IQR: 12–46, rangingbetween1and87years),with no
significant differences between the communities (P = 0.656).
Thirteen samples were of low volume and were arbitrarily
tested only for anti-HEV IgG.
TABLE 1
Prevalence of anti-HAV IgG stratified by age cohort and gender in two rural communities of the Bolivian Chaco
Bartolo Positive % Ivamirapinta Positive % Total Positive %
Gender
Female 48 40 83.3 77 77 100 125 117 93.6
Male 55 53 96.3 64 62 96.9 119 115 96.6
Age classes
1–5 8 1 12.5 6 6 100 14 7 50
6–10 11 8 72.2 20 19 95 31 27 87.1
11–20 16 16 100 39 39 100 55 55 100
21–30 20 20 100 13 13 100 33 33 100
31–40 18 18 100 19 19 100 37 37 100
41–50 10 10 100 13 13 100 23 23 100
51–60 8 8 100 9 9 100 17 17 100
³ 61 12 12 100 22 21 95.5 34 33 97.1
Total 103 93 90.3 141 139 98.6 244 232 95.1
HAV = hepatitis A virus; IgG = immunoglobulin G.
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Hepatitis A virus seroprevalence. Of the 244 serum
samples tested for anti-HAV IgG, 232 (95.1%, 95% CI:
92.4–97.8) were positive. Seroprevalence was significantly
higher in Ivamirapinta than that in Bartolo (98.6% versus
90.3%,P=0.003). The imbalanceof seroprevalenceobserved
between both communities was accounted for by differences
in young children aged 1–5 years (12.5% in Bartolo versus
100% in Ivamirapinta, P = 0.005), whereas in both communi-
ties, it was found to be ³ 95% in individuals aged > 10 years
(Table 1). Anti-HAV positivity was strongly associated with
increasing age (odds ratio [OR]: 1.14 for each 1-year increase,
95% CI: 1.05–1.26, P = 0.003). Stratification by age cohort
showed that exposure occurred predominantly in subjects
aged up to 10 years, reaching 100% in the second decade of
life. No difference was observed in the gender distribution of
seropositives (P = 0.377).
Hepatitis E virus seroprevalence. When using the HEV
IgG Dia.pro kit, 7/257 samples gave a borderline result and
were excluded from further statistical analysis.Overall, 87/250
of individuals studiedwere anti-HEV IgGpositive (34.8%,95%
CI: 28.9–40.7). Therewas nodifference inHEVseroprevalence
in males and females (P = 0.560) or the two communities
tested (P = 0.741). The seroprevalence of HEV steadily in-
creased with age (OR: 1.05 for each 1-year increase, 95% CI:
1.04–1.07, P < 0.001), exceeding 50% by the fifth decade of
life (Table 2).
Using the Wantai anti-HEV IgG kit, the results were similar
with 77 positives of 251 individuals tested. After exclusion of
six borderline results, the seroprevalencewas 30.7% (95%CI:
25.0–36.4). Concordance between both assays was excellent
(k = 0.95).
Helicobacter pylori seroprevalence. Among 244 samples
tested for anti–H. pylori IgG, 143 were positive (58.6%, 95%
CI: 52.4–64.8). No statistical differences were found in distri-
bution between genders (P = 0.172) or communities (P =
0.592). In common with the other infections, H. pylori sero-
prevalence increased with age (OR: 1.02 for each 1-year in-
crease, 95%CI: 1.01–1.03,P=0.003) in subjects up to the age
of 40 years, after which it ‘plateaued’ (Table 3).
Coinfections. Among 237 individuals with interpretable
results, coinfection was found in 166 (70%), including 82
(34.6%) exposed to both HAV and HEV and 53 (22.4%) ex-
posed to all three pathogens. No significant age-corrected
associations were found between H. pylori infection and HAV
(OR: 1.61, 95%CI: 0.37–6.95, P = 0.516), HEV (OR: 0.82, 95%
CI: 0.43–1.56, P = 0.546), or HAV/HEV (OR: 0.88, 95% CI:
0.46–1.68, P = 0.706) exposure. Similarly, no association was
found between HAV and HEV exposure (P = 0.748).
DISCUSSION
In this study, the seroprevalence of HAV, HEV, andH. pylori
in the Bolivian Chaco was surveyed, 10 to 20 years after the
last assessment in the same area. Hepatitis A virus seropre-
valence was 95.1%, with universal exposure after the first
decade of life (Figure 1A). This finding is unchanged from
TABLE 2
Prevalence of anti-HEV IgG (Dia.pro kits) stratified by age cohort and gender in two rural communities of the Bolivian Chaco
Bartolo Positive % Ivamirapinta Positive % Total Positive %
Gender
Female 50 14 28 77 28 36.4 127 42 33.1
Male 59 27 45.8 64 18 28.1 123 45 36.6
Age classes
1–5 11 0 0 7 0 0 18 0 0
6–10 13 1 7.7 21 0 0 34 1 2.9
11–20 16 2 12.5 39 7 17.9 55 9 16.4
21–30 21 8 38.1 13 5 38.5 34 13 38.2
31–40 16 8 50 18 7 38.9 34 15 44.1
41–50 12 8 66.7 12 6 50 24 14 58.3
51–60 8 5 62.5 9 6 66.7 17 11 64.7
³ 61 12 9 75 22 15 68.2 34 24 70.5
Total 109 41 37.6 141 46 32.6 250 87 34.8
HEV = hepatitis E virus; IgG = immunoglobulin G.
TABLE 3
Prevalence of anti–Helicobacter pylori IgG stratified by age cohort and gender in two rural communities of the Bolivian Chaco
Bartolo Positive % Ivamirapinta Positive % Total Positive %
Gender
Female 48 23 47.9 77 45 58.4 125 68 54.4
Male 55 39 70.9 64 36 56.3 119 75 63
Age classes
1–5 8 1 12.5 6 2 33.3 14 3 21.4
6–10 11 6 54.5 20 7 35 31 13 41.9
11–20 16 9 56.3 39 23 59 55 32 58.2
21–30 20 12 60 13 7 53.8 33 19 57.6
31–40 18 14 77.8 19 12 63.2 37 26 70.3
41–50 10 7 70 13 9 69.2 23 16 69.6
51–60 8 5 62.5 9 6 66.7 17 11 64.7
³ 61 12 8 66.7 22 15 68.2 34 23 67.6
Total 103 62 60.2 141 81 57.4 244 143 58.6
IgG = immunoglobulin G.
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previous observations in Bolivia and Peru and is in line with
World Health Organization (WHO) estimates for Andean Latin
American countries, both in rural and urban areas.10–12 Pre-
viously, a significant decrease in HAV seroprevalence among
children aged 1–5 was years observed from 1987 to 1997
(from 86.9% to 64.7%). However, in the current study, a de-
crease inHAVseroprevalencewasseenonly in thecommunity
of Bartolo (1/8, 12.5%) but not in Ivamirapinta (6/6, 100%).
This observed difference in prevalence in such very young
children between Bartolo and Ivamirapinta does not reflect
differences in sanitation between both communities, and it
cannot be explained by family or household clustering (data
not shown). These results need to be interpreted with caution,
given the low number of children studied in this age cohort.
A decline in circulating HAV among children is consistent
with reports from many parts of the world, where anti-HAV
epidemiology is changing, probably because of improve-
ments in socioeconomic conditions and local health educa-
tion.10 Since the end of the last century, the prevalence of
anti-HAV antibodies has decreased in several Latin American
countries, including Argentina, Brazil, Venezuela, Chile, and
Uruguay.13,14 As a consequence of the reduction in viral
FIGURE 1. (A–C) Seroprevalence trends of hepatitis A virus (HAV) (A), hepatitis E virus (HEV) (B), and Helicobacter pylori (C) in the human
population of rural communities of the Bolivian Chaco: 1987–2013.
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exposure during early childhood, the peak age of infections is
shifting to middle childhood or later, resulting in more clinical
cases in adolescents and adults and an increased potential
for clinically overt outbreaks. In these countries, monitoring
of HAV epidemiology, especially in younger age cohorts, is
important, as such data will inform preventive intervention
strategies, such as vaccination campaigns.
The HEV seroprevalence was found to be an order of
magnitude higher, using both newer Dia.pro (34.8%) and the
well-validated Wantai kits (30.7%), compared with that re-
ported in previous surveys from Bolivia and Latin America,
including our studies in the Bolivian Chaco7–9,15 (Figure 1B).
The finding is not surprising, considering that commercial
assays for anti-HEV IgG detection show highly variable per-
formance.16 The use of more sensitive assays has led to a
three-times or four-times increase in estimates of HEV sero-
prevalence, including countries in Asia, where HEV gt 1 is the
dominant circulating gt, and Europe, where gt 3 and 4 zoonotic
HEV is endemic.17–19 Of note, in the community of Bartolo,
previously surveyed in 2006 using an older version of the
commercial ELISA kit Dia.pro, a five to six-times higher prev-
alence was observed (38% versus 7%).9 Because no HEV or
jaundice outbreaks have been reported in recent years in this
area, these discrepancies are likely due to the improved per-
formance of the newer tests, whose reliability is corroborated
by the excellent interassay agreement.20 The finding of high
HEV seroprevalence in the areas tested, the lack of relation-
ship regarding coinfection with other common fecal–oral
pathogens, together with the lack of outbreaks of jaundice/
deaths in pregnant females, and our previous observations of
HEV gt 3 in both pigs and humans from the same community
suggest that the dominant mode of infection in the areas
studied is likely to be zoonotic. This is congruent with recent
studies from several countries in South America, which shows
that HEV gt 3 is the dominant circulating gt and that the epi-
demiology is similar to that seen in locally acquired zoonotic
infections in Europe.21–24 However, previously reported se-
quencing data on porcine and human strains, detected in the
Bartolo community, suggest that the source of human HEV
infection is unlikely to be from the local pig population, as there
was poor sequence homology between porcine HEV (gt 3i)
and human HEV (gt 3e).25
The seroprevalence of H. pylori was 58.6%, with an age-
dependent distribution, reaching a plateau around 70% af-
ter the fourth decade of life. Unpublished data (A. Bartoloni)
from the same area reported similar results in 1997 (61%)
(Figure 1C). Previously, a high H. pylori seroprevalence (44%)
was reported among children aged 6 months to 9 years from
17 rural communities in the Santa Cruz Department, Bolivia.
This rose to 64% when just considering individuals aged 7–9
years.26 Two cross-sectional surveys onH. pylori infections in
Bolivia, conducted in thecity of Sucre and in two villages of the
eastern territories using the urea breath test (UBT), reported
a prevalence of 74% and 80%, respectively.27,28 The higher
prevalence found in the latter studiesmight beattributed to the
higher sensitivity of UBT in comparison with serology. Sero-
logical assays for H. pylori cannot distinguish between on-
going and resolved infections because specific IgG persist for
months or years after a successful eradication of the bacte-
rium. Likewise, seronegativity does not entirely exclude the
possibility of a previous infection.29 However, it seems likely
that the observed prevalence in the current study is a
reasonable estimate of the cumulative exposure burden over
time, as local access to diagnostic tests and treatment of
H. pylori infection are extremely limited. In Bolivia, stomach
cancer, which is themain clinical sequela ofH. pylori infection,
was one of the five most frequently diagnosed cancers, as in
many other countries of Latin America and, in 21% of cases it
affects people younger than 50 years.30
In the population we studied, no association was found
between HAV, HEV, and H. pylori seropositivity when cor-
rected for age. These findings are consistent with the con-
clusion of a recent systematic review.6 Although serostatus
may not be an accurate marker for this association, our find-
ings suggest that these three infections do not share the same
route of transmission. This would fit with current notions of
source and routes of infection: HAV is transmitted through the
fecal–oral route,with humans as themain reservoir; gt 3HEV is
a porcine zoonosis, most likely due to either consumption of
infected pork meat or close contact with infected animals;
H. pylori seems to spread through multiple routes, depending
on cultural and environmental conditions.6
The main limitation of the study is that the survey involved
only two communities with a relatively small number of study
participants. Moreover, it was not possible to weight the re-
sults back to the overall village population because therewas
no accurate census of the two communities. Thus, our find-
ings may not be completely representative of the entire
Chaco region. However, given that the Bolivian Chaco is a
homogeneous ecological zone and the rural populations
share the same hygienic and sanitary living conditions, it
seems unlikely that there are major geographical differences in
the distributionof such infectionswithin the region. Indeed, there
seems to be a strong relationship between poor socioeconomic
conditions/poor hygiene standards and the seroprevalence of
HAV, HEV (at least for gt 1), and H. pylori infections in many
locations across the world. The high prevalence of these infec-
tions found in theBolivianChacosuggests that significantefforts
are still needed to reduce transmission and to improve health/
sanitary conditions in this area, a notion that is highlighted by the
high prevalence of intestinal parasitic infections in the same
area.31,32 Interventions should be inspired by the WASH princi-
ples, endorsed by the WHO, and focused on access to safe
drinkingWAter, improvement of Sanitation facilities andHygiene
promotion by health education.33 As far as HEV is concerned,
further studies are needed to improve our understanding of
HEV epidemiology, especially regarding the main source of
human infection in South America in general and Bolivia in
particular.
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